Please note: The information displayed on this page might be outdated.
Synthekine: Operator of a biopharmaceutical company focused on creating a new class of immunomodulating drugs. The company is generating an array of "synthetic" cytokines that possess greater cell selectivity, bias cell signaling, and/or possess completely new biological activities relative to their native counterpart, enabling potential treatment of a range of diseases, from cancer to autoimmune disorders.
Based in...
US - Pacific
1505 O'Brien Drive
Suite D
Menlo Park, CA 94025
United States

Company Participants at Winter Private Company Showcase

Debanjan Ray
Synthekine, CEO
Debanjan has served as Synthekine’s President and Chief Executive Officer since the company’s formation in 2019. Before joining Synthekine, he served as Chief Financial Officer and head of corporate development at CytomX Therapeutics, capping an eight-year tenure in roles of increasing responsibility. Debanjan helped advance CytomX from an early stage platform technology to multi-asset clinical stage company, led financing efforts and closed multiple collaborations with Bristol Myers Squibb, AbbVie, Amgen, Pfizer and Immunogen that generated over $500 million in upfront payments and up to $5 billion in milestones. Prior to joining CytomX in 2011, he was VP of Business Development at Itero Biopharmaceuticals. Earlier in his career, Debanjan held positions in business development at Portola Pharmaceuticals, in the life sciences venture practice at J.P. Morgan Partners and as a business analyst in the healthcare practice at McKinsey & Company. Debanjan received his MBA from The Wharton School, University of Pennsylvania, and his BS in chemical engineering and biology from the Massachusetts Institute of Technology.